Recombinant human VEGF Receptor 2 protein (Active) (ab106310)
Key features and details
- Expression system: Insect cells
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
Description
-
Product name
Recombinant human VEGF Receptor 2 protein (Active)
See all VEGF Receptor 2 proteins and peptides -
Biological activity
Measured by its ability to inhibit the VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells.
-
Purity
> 95 % SDS-PAGE.
Affinity purified. -
Expression system
Insect cells -
Accession
-
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
The soluble receptor protein consists of the first 6 extracellular domains and contains the unique C-terminal end of native Human soluble VEGF Receptor 2 (CGRETILDHSAEAVGMP) [Albuquerque et al.,Nature Medicine,2009] generated by alternative splicing. -
Predicted molecular weight
105 kDa
-
Specifications
Our Abpromise guarantee covers the use of ab106310 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Functional Studies
SDS-PAGE
-
Form
Lyophilized -
Additional notes
Endotoxin level: < 0.1 ng per ug. Measured by its ability to bind to immobilized recombinant Human VEGF165 in a functional ELISA. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Constituents: 0.4875% MES, 0.87% Sodium chloride
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
ReconstitutionThe lyophilized powder should be reconstituted in water or PBS to a concentration not lower than 100 µg/ml.
General Info
-
Alternative names
- CD309
- CD309 antigen
- EC 2.7.10.1
see all -
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
Images
-
Inhibition of the VEGF165-induced proliferation in HUVECs by soluble VEGFR-2/KDR. VEGF165 (10ng/ml) was preincubated with increasing amounts of sVEGFR-2/KDR for 1h and then added to the cells.
-
Inhibition of the VEGF165-induced proliferation of HUVE cells by recombinant human and mouse endogenous sKDR and sFlk-1 HUVECs were stimulated with 10 ng/ml VEGF165, both soluble receptors were added with a 100X excess.
-
SDS-PAGE showing ab106310
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab106310 has not yet been referenced specifically in any publications.